SCHEMBL21200922

SCHEMBL21200922

COc1cccc(C(=O)Nc2cccc(C(C)Sc3nncn3C)c2)c1

nearest known ligand 0.82

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CBLB Q13191 20/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29867039 1.00 CBLB (0.82) CBLB
SCHEMBL29867519 0.91 CBLB (0.80) CBLB
SCHEMBL21201093 0.91 CBLB (0.80) CBLB
SCHEMBL21211824 0.90 CBLB (1.00) CBLB
SCHEMBL29866741 0.90 CBLB (1.00) CBLB
SCHEMBL21212269 0.88 CBLB (1.00) CBLB
SCHEMBL29867862 0.88 CBLB (1.00) CBLB
SCHEMBL29867125 0.87 CBLB (1.00) CBLB
SCHEMBL21212666 0.87 CBLB (1.00) CBLB
SCHEMBL21212355 0.87 CBLB (1.00) CBLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3743063-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF Nurix Therapeutics, Inc. (US) 2020-12-02 EP disclosed
WO-2019148005-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF NURIX THERAPEUTICS, INC. (US) 2019-08-01 WO disclosed
WO-2019148005-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF NURIX THERAPEUTICS, INC. (US) 2019-08-01 WO disclosed